As Transkaryotic Therapies Inc. revealed a weak hand regarding Replagal (agalsidase alfa), all eyes turned to competitor Genzyme General, which has been playing its cards close to the vest. (Bioworld Today)
About two weeks after filing a shelf registration statement to sell up to $250 million in securities, Myriad Genetics Inc. is raising $57.3 million through a pursuant offering of 3 million shares of stock. (BioWorld Today)
About one month after saying it would suspend recruitment in a Phase III trial of its lead prostate cancer drug, sell some fixed assets and consider other options for the future, Northwest Biotherapeutics Inc. has made more cuts and may shut down entirely. (BioWorld Today)
Study, patience and a kind of indomitable hope: such are the qualities required of the biotechnology investor, and of researchers in the HIV field. (BioWorld Financial Watch)
There's a simple way to describe leukemia - it's a blood cancer that starts in the bone marrow and is recognized by the proliferation of leukocytes, or white blood cells - but sifting through the subtypes, available treatments and would-be therapies is hardly an easy task. (BioWorld Financial Watch)
A longstanding squabble between Amgen Inc. and Johnson & Johnson over epoetin alfa ended last week with an arbitrator's $150 million decision favoring the former, just as another skirmish - not legal - began to heat up between the pair. (BioWorld Financial Watch)
